Quantcast

Latest Merck KGaA Stories

2014-09-27 08:21:20

- Global winners selected for their unique research projects that have the potential to advance research for the personalized treatment of solid tumors ROCKLAND, Mass., Sept. 27, 2014 /PRNewswire/ -- EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million. The 2014 winners were formally announced at an awards ceremony coinciding with the annual...

2014-09-19 04:21:46

ROCKLAND, Massachusetts, September 19, 2014 /PRNewswire/ -- - The first grants awarded to coincide with the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting - Investment supports innovative projects for the advancement of science and medical research in the field of growth EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the first recipients of the Grant for Growth Innovation (GGI) for...

2014-09-18 12:29:37

DARMSTADT, Germany, September 18, 2014 /PRNewswire/ -- - Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive Board - Belen Garijo appointed new member of the Executive Board - Changes effective from January 1, 2015 Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belen Garijo (54) was...

2014-09-17 08:29:31

- Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand its oncology pipeline SAN FRANCISCO, Sept. 17, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and...

2014-09-12 12:25:16

DARMSTADT, Germany, September 12, 2014 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Luciano Rossetti, Global Head of Research & Development at the biopharmaceutical division, said: "While the data...

2014-09-12 08:25:21

- Research grants awarded for five out of more than 200 proposals, highlighting continued commitment to multiple sclerosis (MS) ROCKLAND, Mass., Sept. 12, 2014 /PRNewswire/ -- EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the recipients of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and...

2014-09-11 12:22:23

-- Providing IVF clinicians objective embryo viability data and another tool to support patient outcomes MISSISSAUGA, ON, Sept. 11, 2014 /CNW/ - EMD Serono, Canada, a subsidiary of Merck KGaA Darmstadt, Germany announced today the launch of the Eeva (®) Test in Canada. In April, Merck Serono, a biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced an exclusive licensing agreement with Auxogyn Inc. for the rights to commercialize the Eeva (®) Test in Europe...

2014-09-10 08:32:02

- EMD Serono provides funding for ACP's multicenter longitudinal OPT-UP clinical study ROCKLAND and WALTHAM, Mass., Sept. 10, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany and the Accelerated Cure Project for Multiple Sclerosis today announced a lead founding sponsor agreement to help launch the Optimizing Treatment--Understanding Progression (OPT-UP) study. http://photos.prnewswire.com/prnvar/20140902/141783...

2014-09-09 16:25:56

- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression, and 'no evident disease activity' (NEDA) measure for interferon beta-1a SC vs. interferon beta-1a IM ROCKLAND, Mass., Sept. 9, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the division's multiple sclerosis...

2014-09-02 08:31:32

ROCKLAND, Mass., Sept. 2, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products. http://photos.prnewswire.com/prnvar/20140902/141784 Bringing more than 20 years of experience leading global and...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'